AB-005

Summary

AB-005 or [1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

AB-005
Legal status
Legal status
Identifiers
  • [1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone
CAS Number
  • 895155-25-6 checkY
PubChem CID
  • 11537652
ChemSpider
  • 9712433
UNII
  • TPY5M47AYQ
ChEMBL
  • ChEMBL571330
Chemical and physical data
FormulaC23H32N2O
Molar mass352.522 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CC4CCCCN4C)C
  • InChI=1S/C23H32N2O/c1-22(2)21(23(22,3)4)20(26)18-15-25(19-12-7-6-11-17(18)19)14-16-10-8-9-13-24(16)5/h6-7,11-12,15-16,21H,8-10,13-14H2,1-5H3
  • Key:MOBWRRIAIHYXLB-UHFFFAOYSA-N

Legal status edit

In 2013, psychoactive products in New Zealand containing this drug were given interim approval under psychoactive substances legislation.[2]

See also edit

References edit

  1. ^ Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. (January 2010). "Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity". Journal of Medicinal Chemistry. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
  2. ^ "Interim Product Approvals". Ministry of Health. Archived from the original on 21 August 2013. Retrieved 2 January 2013.